| Trial ID: | L4606 |
| Source ID: | NCT06256419
|
| Associated Drug: |
Glp-1 Receptor Agonist
|
| Title: |
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus|Susceptibility, Genetic
|
| Interventions: |
DRUG: GLP-1 receptor agonist|DRUG: responders group and nonresponders group
|
| Outcome Measures: |
Primary: Change from baseline HbA1c and baseline weight at 6 month, In order to observe the change from baseline HbA1c and baseline weight at 6 month after GLP-1 RA treatment, 6 month after GLP-1 RA treatment|To identify and evaluate the variable factors influencing GLP-1 RA efficacy, The variable factors that predict the efficacy of GLP-1 RA were identified and the weight these variables on the efficacy was assessed, 1 month after sample integration|Genotype identification in patients with T2DM, Blood samples were collected from T2DM patients for genotyping, 1 month after sample collecting | Secondary: Incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment, To evaluate the incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment, including gastrointestinal reaction and hypoglycemia, 6 months after GLP-1 RA treatment
|
| Sponsor/Collaborators: |
Sponsor: The Affiliated Hospital of Xuzhou Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2024-01-01
|
| Completion Date: |
2028-01-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-02-13
|
| Locations: |
China, Jiangsu, Department of Endocrinology, Xuzhou, 221006, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06256419
|
